Education
About Us
Working with TipRanks
Follow Us
SMAP - AI Analysis
Top Page
Amplify Small-Mid Cap Equity ETF (SMAP)
Rating:71Outperform
Price Target:
$28.00
Positive Factors
Strong Top Holdings
Several top holdings, such as Monolithic Power and Curtiss-Wright, have delivered strong year-to-date performance, supporting the fund’s overall returns.
Sector Diversification
The ETF is spread across nine sectors, including Industrials, Technology, and Health Care, reducing reliance on any single industry.
Steady Performance
The ETF has shown consistent positive returns over the past month, three months, and year-to-date, indicating solid momentum.
Negative Factors
High Geographic Concentration
With over 99% exposure to U.S. companies, the fund lacks diversification across global markets.
Mixed Holding Performance
Some top holdings, such as West Pharmaceutical Services and Watsco, have underperformed year-to-date, which could drag on overall returns.
Moderate Expense Ratio
The ETF’s expense ratio is higher than many low-cost alternatives, potentially reducing net investor returns over time.
SMAP vs. SPDR S&P 500 ETF (SPY)
AUM1.26M
RegionNorth America
Expense Ratio0.60%
Beta0.94
IssuerAmplify
Inception DateOct 23, 2024
Dividend Yield0.49%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume142
30 Day Avg. Volume451
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
29.13Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering59
SMAP Summary
The Amplify Small-Mid Cap Equity ETF (Ticker: SMAP) focuses on small and mid-sized companies in the U.S., offering investors a chance to tap into the growth potential of businesses that are often more agile and innovative than larger corporations. It includes companies like Monolithic Power and West Pharmaceutical Services, which are leaders in their industries. This ETF is ideal for those looking to diversify their portfolio and invest in firms that could drive future economic growth. However, new investors should know that small and mid-cap stocks can be more volatile than large-cap stocks, meaning their prices can rise and fall quickly.
How much will it cost me?The Amplify Small-Mid Cap Equity ETF (SMAP) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed, which typically involves more research and trading compared to passively managed funds. Active management aims to outperform the market by selecting specific investments, which can justify the higher cost.
What would affect this ETF?The Amplify Small-Mid Cap Equity ETF (SMAP) could benefit from economic growth and innovation in sectors like technology and industrials, which make up a significant portion of its holdings. However, it may face challenges from rising interest rates or economic slowdowns, which can disproportionately impact smaller companies. Additionally, its U.S.-focused exposure means it is sensitive to domestic economic and regulatory changes.
SMAP Top 10 Holdings
The Amplify Small-Mid Cap Equity ETF (SMAP) is leaning heavily on industrials and technology, with names like Monolithic Power and Curtiss-Wright providing a steady lift thanks to strong financial performance and innovation-driven growth. However, Tyler Technologies and Watsco are dragging the fund, with valuation concerns and bearish momentum weighing on their recent performance. While the ETF’s focus on U.S.-based small and mid-cap companies offers exposure to agile and emerging businesses, the mixed results from its holdings highlight the challenges of navigating this dynamic segment of the market.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Monolithic Power | 4.05% | $50.33K | $52.09B | 43.23% | 78 Outperform | |
| West Pharmaceutical Services | 3.62% | $45.01K | $20.04B | -9.54% | 76 Outperform | |
| Stifel Financial | 3.18% | $39.50K | $12.03B | 13.66% | 69 Neutral | |
| Curtiss-Wright | 3.10% | $38.50K | $22.51B | 73.21% | 77 Outperform | |
| Eagle Materials | 2.93% | $36.37K | $6.96B | -24.81% | 69 Neutral | |
| Watsco | 2.67% | $33.15K | $14.57B | -24.24% | 73 Outperform | |
| Tyler Technologies | 2.62% | $32.50K | $20.57B | -21.06% | 69 Neutral | |
| PTC | 2.39% | $29.68K | $23.64B | 6.50% | 74 Outperform | |
| NVR | 2.36% | $29.33K | $20.79B | -20.84% | 64 Neutral | |
| Markel | 2.35% | $29.22K | $24.44B | 25.70% | 73 Outperform |
SMAP Technical Analysis
Negative
―
Price Trends
24.94
Negative
24.68
Negative
24.09
Positive
Market Momentum
0.03
Positive
43.67
Neutral
23.43
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SMAP, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 25.05, equal to the 50-day MA of 24.94, and equal to the 200-day MA of 24.09, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 43.67 is Neutral, neither overbought nor oversold. The STOCH value of 23.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SMAP.
SMAP Peer Comparison
Comparison Results
Performance Comparison
SMAP
Amplify Small-Mid Cap Equity ETF
24.65
0.23
0.94%
ASCE
Allspring SMID Core ETF
―
―
―
HSMV
First Trust Horizon Managed Volatility Small/Mid ETF
―
―
―
SAEF
Schwab Ariel ESG ETF
―
―
―
MYLD
Cambria Micro and SmallCap Shareholder Yield ETF
―
―
―
EPSB
Harbor SMID Cap Core ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents